Profile data is unavailable for this security.
About the company
Camurus AB is a Sweden-based research and development based pharmaceutical company with a focus on the development and commercialization of specialty medicines, providing patients suffering from serious and chronic disease, such as opioid dependence, pain, cancer, acromegaly, and neuroendocrine tumors. The Company has a diversified research portfolio, which includes five products in clinical trials, and a number of additional product candidates in the pre-clinical phase. The Company’s product pipeline represents a mix of in-house and partnered projects in different development phases. Camurus AB is the parent company of the Group, which comprises four legal entities, namely Camurus Inc, Cubosome Inc, Camurus Development AB and Bioimplant Scandinavia AB.
- Revenue in SEK (TTM)46.97m
- Net income in SEK-199.72m
- Incorporated--
- Employees81.00
- LocationCamurus ABSolvegatan 41LUND 223 62SwedenSWE
- Phone+46 462865730
- Fax+46 462865739
- Websitehttps://www.camurus.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calliditas Therapeutics AB | 0.00 | -128.37m | 1.51bn | 10.00 | -- | 2.42 | -- | -- | -4.36 | -4.36 | 0.00 | 18.74 | 0.00 | -- | -- | 0.00 | -35.91 | -- | -38.23 | -- | -- | -- | -- | -- | -- | -1,379.31 | 0.00 | -- | -- | -- | -52.51 | -- | -- | -- |
| Alligator Bioscience AB | 52.66m | -106.94m | 1.53bn | 53.00 | -- | 3.06 | -- | 29.01 | -1.50 | -1.50 | 0.7377 | 6.99 | 0.0914 | -- | 22.41 | 1,120,511.00 | -18.56 | -- | -19.37 | -- | -114.25 | -- | -203.06 | -- | -- | -- | 0.00 | -- | -2.34 | -- | -31.85 | -- | -- | -- |
| Bergenbio ASA | 0.00 | -198.66m | 1.55bn | 24.00 | -- | 3.78 | -- | -- | -3.67 | -3.67 | 0.00 | 7.09 | 0.00 | -- | -- | 0.00 | -44.91 | -- | -48.04 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -40.38 | -- | -- | -- |
| Infant Bacterial Therapeutics AB | 0.00 | -25.52m | 1.64bn | -- | -- | 2.93 | -- | -- | -3.16 | -3.16 | 0.00 | 51.74 | 0.00 | -- | -- | -- | -7.59 | -25.10 | -7.74 | -26.89 | -- | -- | -- | -18,575.38 | -- | -26.65 | 0.00 | -- | 46.91 | -- | 5.12 | -- | -- | -- |
| Oasmia Pharmaceutical AB | 1.79m | -153.28m | 1.91bn | 57.00 | -- | 5.28 | -- | 1,070.58 | -0.9064 | -0.9064 | 0.0106 | 1.80 | 0.0031 | -0.5356 | 1.05 | 30,775.86 | -26.27 | -25.38 | -37.11 | -39.72 | 460.62 | 591.85 | -8,587.68 | -5,423.88 | 0.574 | -5.66 | 0.2353 | -- | 1,742.44 | -- | 26.36 | -- | -19.03 | -- |
| Orexo AB | 747.10m | 113.20m | 2.41bn | 102.00 | 21.61 | 5.69 | 18.02 | 3.23 | 3.23 | 3.23 | 21.43 | 12.27 | 0.6666 | 0.7897 | 2.96 | 8,301,111.00 | 10.10 | -7.72 | 21.47 | -11.55 | 76.08 | 79.94 | 15.15 | -12.33 | 1.78 | 18.30 | 0.43 | -- | -8.81 | 14.56 | -20.00 | -- | -22.62 | -- |
| Immunovia AB (publ) | 267.96k | -76.20m | 2.46bn | 45.00 | -- | 5.69 | -- | 9,177.36 | -4.24 | -4.24 | 0.0149 | 24.97 | 0.0007 | -- | 0.0387 | 7,881.18 | -20.01 | -- | -20.60 | -- | -11,463.52 | -- | -28,437.53 | -- | -- | -- | 0.00 | -- | -15.97 | -- | -207.22 | -- | -- | -- |
| Camurus AB | 46.97m | -199.72m | 2.57bn | 81.00 | -- | 7.57 | -- | 54.74 | -5.32 | -5.32 | 1.25 | 8.85 | 0.0977 | 0.7041 | 3.48 | 661,605.60 | -41.53 | -- | -51.45 | -- | 92.25 | -- | -425.17 | -- | 2.48 | -- | 0.00 | -- | -52.25 | -- | -135.30 | -- | -- | -- |
| Nordic Nanovector ASA | 52.75k | -353.38m | 2.74bn | 40.00 | -- | 5.86 | -- | 51,893.64 | -6.83 | -6.83 | 0.001 | 8.96 | 0.00007 | -- | 0.0018 | 1,351.35 | -48.95 | -29.75 | -55.47 | -32.41 | -- | -- | -669,926.00 | -43,551.55 | -- | -- | 0.00 | -- | -3.82 | 15.31 | -24.76 | -- | 100.25 | -- |
| IRLAB Therapeutics AB | 15.00k | -68.48m | 2.76bn | 19.00 | -- | 12.06 | -- | 184,117.70 | -9.30 | -9.30 | 0.002 | 28.53 | 0.00007 | -- | 0.0035 | 681.82 | -32.11 | -- | -34.32 | -- | -333,453.30 | -- | -456,540.00 | -- | -- | -311.70 | 0.00 | -- | -24.31 | -- | -31.69 | -- | -- | -- |
Data as of Jan 18 2019. Currency figures normalised to Camurus AB's reporting currency: Swedish Krona SEK
17.95%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Max Mitteregger Kapitalf�rvaltning ABas of 03 Dec 2018 | 2.49m | 6.48% |
| SEB Investment Management ABas of 31 Dec 2017 | 951.27k | 2.48% |
| Catella Fondf�rvaltning ABas of 31 Dec 2018 | 915.65k | 2.39% |
| Fj�rde AP-fondenas of 31 Dec 2017 | 797.73k | 2.08% |
| Swedbank Robur Fonder ABas of 31 Dec 2018 | 706.46k | 1.84% |
| Enter Fonder ABas of 31 Dec 2017 | 682.87k | 1.78% |
| Xact Kapitalf�rvaltning ABas of 31 Dec 2018 | 179.94k | 0.47% |
| Andra AP-fondenas of 30 Jun 2018 | 144.69k | 0.38% |
| Skandia Investment Management ABas of 30 Nov 2018 | 13.93k | 0.04% |
| Danske Bank A/S (Investment Management Sweden)as of 17 Jan 2019 | 10.47k | 0.03% |
More ▼
Data from 31 Dec 2016 - 18 Jan 2019Source: FactSet Research Systems Inc.
